CSL to acquire Chinese blood plasma fractionator

The Australian blood plasma company buys a majority stake in a Chinese firm for $352 million in hopes of broadening its offering in China. It's the first such deal by a foreign firm.

Australian blood plasma giant CSL is to strengthen its footprint in China with a $352 million deal for an 80 per cent stake in a Chinese plasma factionator.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media